RxDoctor Payments Data

Timothy Vellinga, MD

Interventional Cardiology · Summit, WINPI 1336109198

Payments from drug & device makers

$2,536in general payments, 2019–2025

Across 109 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Abiomed$489
  • Shockwave Medical, Inc$436
  • Cvrx, Inc.$222
  • Boston Scientific$103
  • Chiesi USA, Inc.$89
  • plus $187 from 5 others

What the payments were for

  • Food & beverage$2,536100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,536 in reported general payments places this provider in the 30th percentile of 118 interventional cardiology providers in Wisconsin.

See all interventional cardiology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$116,876
Medicare patients
985
Services billed
1,805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban189$232,828
XareltoRivaroxaban99$135,020
Repatha SureclickEvolocumab42$34,087
EntrestoSacubitril/Valsartan21$26,291
Praluent PenAlirocumab18$26,276
FarxigaDapagliflozin Propanediol18$22,043
JardianceEmpagliflozin11$19,097
Repatha SyringeEvolocumab13$12,359
Metoprolol Succinate506$8,473
Atorvastatin Calcium493$7,247
Rosuvastatin Calcium247$3,881
Losartan Potassium174$2,649
ClopidogrelClopidogrel Bisulfate176$2,174
Lisinopril198$1,984
Ezetimibe99$1,978

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$45$26,29121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 118 interventional cardiology providers in Wisconsin.

Other interventional cardiology in Summit

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →